Replies to post #679 on Israel-Medical-Healthcare

[genisi]

I know Heparin has a huge MC but MNTA might be facing long setback with the FDA while PLX will have the door open. GENZ are selling Glucocerebrosidase for around $1B and PLX's platform is cheaper for production they will capture the market quickly IMO.
Considering PLX agreement with TEVA, it looks like this is just the beginning so $500 is not science fiction.

I don't know if you can buy stocks on TASE, just called my broker firm and they they can't serve non Israelis. I think that can only be done via a bank. Will ask tomorrow (banks are closed now).
I'm curios, when and how did you found out about PLX?

genisi

[midastouch017]

TASE exec: Biomed IPOs will maintain fast pace
8 R&D companies, 7 in the life sciences, held IPOs during the first quarter.
Gali Weinreb 22 Mar 07 18:02
“We expect to see the same rate of IPOs by biomedical companies in the next quarter as we’ve had to date. Some of the pending IPOs will be larger than the average we saw in 2006, and will be closer in value to, or even larger than, the IPOs of BiolineRX Ltd. (TASE:BLRX) and Itamar Medical Ltd. (TASE:ITMR),” TASE VP Ronit Harel told “Globes”.
Harel said eight R&D companies held IPOs during the first quarter of 2007, out of 13 IPOs altogether. Seven of the eight R&D companies were in the life sciences. The average IPO size was 2.5 times larger than the average for both the corresponding quarters of 2006 and 2005, when the wave of IPOs by R&D companies began
Harel said, “This is the trend that the TASE anticipated. A rise in the size of IPOs to the point where the TASE will become a legitimate source of capital for R&D companies that have alternative sources. Rosetta Genomics Ltd. (Nasdaq:ROSG) raised only $26 million on Nasdaq, whereas BiolineRX was able to raise $50 million in Tel Aviv.”

Harel said that, over time, the number of institutional investors participating in these IPOs was increasing, and that analysts were learning to recognize and cover the companies. “It’s possible that when more large biomedical companies join the TASE, we’ll be able to launch an index for them.”

Published by Globes [online], Israel business news - www.globes.co.il - on March 22, 2007